https://pubmed.ncbi.nlm.nih.gov/39775763/
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with...
BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 ("MORPHO") was a randomized study of gilteritinib compared with placebo as maintenance...
for patientsmeasurableresidualdiseasemaintenance